What is KalGene Pharmaceuticals?
KalGene Pharmaceuticals, also known as Kalgene Inc., is a biopharmaceutical company dedicated to developing novel therapeutic approaches for Alzheimer's patients. Their primary focus is on enhancing the quality of life for individuals affected by this neurodegenerative condition. The company's lead candidate, KG207, is designed to address critical unmet needs within the Alzheimer's patient and caregiver community. KalGene actively pursues collaborations with various entities to accelerate its research and product development pipeline in this vital therapeutic area.
How much funding has KalGene Pharmaceuticals raised?
KalGene Pharmaceuticals has raised a total of $1.5M across 1 funding round:
Unspecified
$1.5M
Unspecified (2015): $1.5M with participation from Brain Canada, Ontario Brain Institute, and CQDM
Key Investors in KalGene Pharmaceuticals
Brain Canada
Brain Canada is a national organization that champions brain research and aims to improve health outcomes for individuals with brain disorders. They provide crucial funding and support for researchers investigating conditions like ALS, epilepsy, and mental health issues, fostering advancements in neuroscience.
Ontario Brain Institute
The Ontario Brain Institute strives to establish Ontario as a leader in brain research, commercialization, and patient care. The organization focuses on mobilizing research excellence to enhance the lives of those with brain disorders and encourages industry investment in neuroscience technologies.
CQDM
CQDM acts as a catalyst for biopharmaceutical innovation by financing research and development initiatives. The organization unites key stakeholders in the biopharma sector to promote collaboration and innovation, offering various membership tiers and supporting advancements in the industry.
What's next for KalGene Pharmaceuticals?
With the infusion of major enterprise-level capital, KalGene Pharmaceuticals is poised for an accelerated growth trajectory. The company is expected to leverage this investment to advance its flagship KG207 program through critical clinical development stages and potentially expand its research into other neurological disorders. Strategic partnerships and further financing rounds may be anticipated as KalGene aims to solidify its market position and bring its innovative Alzheimer's treatments to patients.
See full KalGene Pharmaceuticals company page
